Published in Gene Therapy Weekly, December 4th, 2003
Final results from phase II studies of ISIS 104838 in patients with rheumatoid arthritis and ISIS 14803 for the treatment of the hepatitis C virus (HCV) were presented at the 67th annual meeting of the American College of Rheumatology and the 54th annual meeting of the American Association for the Study of Liver Diseases, respectively.
Updated results of a phase II study of alicaforsen (ISIS 2302) in patients with pouchitis were presented at the 67th annual scientific meeting of the American College of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.